File downloaded on 2026-11-04
Source URL: https://medicines.health.europa.eu/veterinary/en/600000983087

Acticam 2.5 mg chewable tablets for Dogs

Not authorised

- Meloxicam

Product identification

Medicine name:
Acticam 2.5 mg chewable tablets for Dogs

Active substance:
Meloxicam

Target species:
Dog

Route of administration:
Oral use

Product details

Active substance and strength:
Meloxicam
2.50 milligram(s) / 1.00 Piece

Pharmaceutical form:
Chewable tablet

Anatomical therapeutic chemical veterinary (ATCvet) codes:
QM01AC06

Legal status of supply:
Veterinary medicinal product subject to veterinary prescription

Authorisation status:
Surrendered

Authorised in:
Slovakia

Package description:
10 tablets (10x1) in a carton box. PVC/PVDC-Alu blister pack made of clear PVC/PVDC and Plain Alu foil. Each blister has 10 tablets.
20 tablets (10x2) in a carton box. PVC/PVDC-Alu blister pack made of clear PVC/PVDC and Plain Alu foil. Each blister has 10 tablets.
500 tablets (10x50) in a carton box. PVC/PVDC-Alu blister pack made of clear PVC/PVDC and Plain Alu foil. Each blister has 10 tablets.
100 tablets (10x10) in a carton box. PVC/PVDC-Alu blister pack made of clear PVC/PVDC and Plain Alu foil. Each blister has 10 tablets.

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Generic application (Article 13(1) of Directive No 2001/82/EC)

Marketing authorisation holder:
Ecuphar

Marketing authorisation date:
13/02/2012

Manufacturing sites for batch release:
Accord Healthcare Limited

Responsible authority:
Institute For State Control Of Veterinary Biologicals And Medicaments

Authorisation number:
96/006/DC/12-S

Date of authorisation status change:
13/02/2012

Reference member state:
Netherlands

Procedure number:
NL/V/0134/002

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Combined File of all Documents

This document does not exist in this language (English). You can find it in another language below.